Health committee  There are a lot of questions, Dr. Fry. I will attempt my best. First, in terms of outcomes, wherever possible, obviously, when we do our evaluations, we measure outcomes. Certainly, in the drug studies, what we found in those measurements is it absolutely reduces drug-to-drug ad

Health committee  Absolutely. Privacy is a two-edged sword. On the one hand, it's extraordinarily important. Again, in the projects we fund we insist that it is built up. We have privacy by design right at the front. We insist on a privacy audit for any of the projects we fund. That must be done t

Health committee  As I say, in each of the investments that we are doing, we look at the annual gains that we're making. We have been looking at them on a year-to-year basis, and I know the number that is in my head over the last five years, the accumulated, has been over $6 billion. We have, as

Health committee  First, I should say those are estimates. Clearly the system only has an appetite to digest so much money at any point in time. The issue here, on many occasions, is the take-up rate. The way Canada Health Infoway funds is very simple. From an accountability perspective, if we don

Health committee  There's a large spend in there.

Health committee  Thank you, Dr. Carrie. You saw from the first presentation from Dr. Rossos that one of the first things Canada Health Infoway created was its architecture and blueprint. Quite frankly, if you don't follow that architecture and blueprint, we don't fund you. You have to follow the

Health committee  Thank you for your question. I will begin and then maybe turn it over to Mike. Yes, we've actually had two reports done in terms of the cost and the benefits. One was by McKinsey and the other was by Booz Allen. I can't remember in 2005 which one it was. I think it was the Booz

Health committee  Bonjour, Madam Chair and members of the standing committee. Thank you for this opportunity to appear in front of you. With me is Mike Sheridan, our chief operating officer. It's a real privilege to be on with some of the best clinical innovators that Canada has. I'm very grate

Health committee  Or demoted, depending on which way you look at it.

Public Accounts committee  First, thank you for this opportunity. If I said it would be a real joy to come back, I may have been overstating the case—

Public Accounts committee  —but I will obviously be delighted to come back. I will leave you with this. I often get asked the question, because of its great importance to the transformation of records: why is it taking so long? My response is, why is it taking so long compared to what? When you think a

Public Accounts committee  As I said, we've done a couple of studies. On one of the things we did, again, as far as I know—and I've now been in this job for the last six years and I have a pretty good handle on it internationally—we're one of the only countries that has had a benefit measurement framework

Public Accounts committee  No. We're absolutely going to be reporting on absolute usage of those available files.

Public Accounts committee  I couldn't tell you those numbers. Those are the numbers we're still gathering in terms of the provinces. They measure in a different way, but we certainly will have those numbers to report on.

Public Accounts committee  I'll be delighted to share it with you, sir.